Critical Medicines Act

This page is also available in:

Ongoing (updated on 11/06/2025) - Bureau decision date: 21/01/2025
Reference
CCMI/240-EESC-2025
Opinion Type
Mandatory
Referral
COM(2025) 102 final 2025/0102 COD
Rapporteur
Veselin MITOV
Workers - GR II
Bulgaria
Co-rapporteur
Elżbieta SZADZIŃSKA
(Poland
Plenary session number
597
-
Download — EESC section opinion: Critical Medicines Act
docx
bg
es
cs
da
de
et
el
en
fr
ga
hr
it
lv
lt
hu
mt
nl
pl
pt
ro
sk
sl
fi
sv

Practical Information: 

  • Composition of the Study Group: 
  • Administrator: Jacopo Ernesto CAJA / Santiago DIAZ-DE-VILLEGAS LE BOUFFANT
  • Contact: e-mail

Background:

Recent disruptions, including the COVID-19 pandemic, have exposed vulnerabilities in the EU pharmaceutical supply chain, highlighting the need to adopt a coordinated approach. The Critical Medicines Act aims to enhance patient access to affordable medicines, support industrial competitiveness, and reinforce European strategic autonomy in healthcare.

This EESC mandatory referral opinion will propose actions and recommendations towards the definition of the Critical Medicines Act. The legislations is set to be a crucial step in strengthening the EU’s resilience against medicine shortages. Ensuring a stable and secure supply of essential medicines is vital to protecting public health, preventing crises in healthcare systems, and reducing the EU’s external dependence for important medicines and components.